Real World Treatment Patterns and Clinical Outcomes in Unfit AML Patients Receiving First Line Systemic Treatment or Best Supportive Care (CURRENT)
Not Applicable
- Conditions
- Acute myeloid leukemia
- Registration Number
- JPRN-UMIN000037786
- Lead Sponsor
- AbbVie Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 1762
Inclusion Criteria
Not provided
Exclusion Criteria
AML diagnosis not confirmed Acute Promyelocytic Leukemia Received First line AML treatment within a clinical study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall Survival(OS) OS will be defined as the time (in months) from the date of confirmed diagnosis of AML (i.e., the index date) to death (any cause) as documented in the medical chart. Patients who did not die within the study observation period will be censored on the study end date or the last contact date available in the dataset, whichever occurred first.
- Secondary Outcome Measures
Name Time Method